Lineus Medical Secures $4.6M in Series C Funding to Revolutionize IV Therapy Safety with SafeBreak™ Vascular Device

Lineus Medical™ is excited to announce a significant funding milestone, having raised $4,600,000 to further advance our mission of enhancing patient care during IV therapy. Our company is dedicated to improving patient outcomes by reducing complications associated with IV access, and this new capital infusion will allow us to accelerate the development and distribution of our innovative SafeBreak™ Vascular device. Utilizing a patented "break-away" technology, SafeBreak™ is designed to create a controlled separation in the IV tubing—an essential step that prevents the often costly and dangerous issues arising from dislodged IV lines. With this device, medical professionals are given a reliable solution where, in the short span of a few minutes, a compromised IV component can be swiftly removed and replaced, ensuring the continuity of vital treatment measures and ultimately enhancing the patient’s overall quality of care. The funds raised will be strategically deployed to refine our technology, expand our manufacturing capabilities, and broaden our market reach. By investing in research and development as well as in rigorous clinical validation processes, we are committed to ensuring that SafeBreak™ sets a new standard in IV therapy safety. Additionally, this capital will support initiatives aimed at educating healthcare providers about the benefits of our innovative approach, fostering stronger partnerships, and driving adoption across hospitals and clinics. This funding landmark represents not only a vote of confidence in our pioneering work but also a crucial step forward in our ongoing efforts to minimize IV complications, reduce treatment interruptions, and ultimately safeguard patient health on a broader scale.